Benjamin Frank
Concepts (310)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 21 | 2026 | 1957 | 4.150 |
Why?
| | Echocardiography | 10 | 2026 | 645 | 2.520 |
Why?
| | Heart Defects, Congenital | 15 | 2026 | 920 | 2.260 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2022 | 391 | 1.570 |
Why?
| | Hemodynamics | 12 | 2026 | 1114 | 1.510 |
Why?
| | Pulmonary Artery | 11 | 2025 | 1116 | 1.300 |
Why?
| | Hernias, Diaphragmatic, Congenital | 2 | 2023 | 188 | 1.260 |
Why?
| | Ventricular Dysfunction, Right | 5 | 2026 | 248 | 1.180 |
Why?
| | Pulmonary Veins | 3 | 2025 | 110 | 1.150 |
Why?
| | Endothelin-1 | 2 | 2022 | 177 | 1.150 |
Why?
| | Fontan Procedure | 5 | 2024 | 200 | 1.130 |
Why?
| | Multimodal Imaging | 2 | 2026 | 138 | 1.090 |
Why?
| | Heart Ventricles | 11 | 2026 | 762 | 1.080 |
Why?
| | Stenosis, Pulmonary Vein | 2 | 2025 | 22 | 1.080 |
Why?
| | Cardiac Catheterization | 6 | 2025 | 569 | 1.070 |
Why?
| | Kynurenine | 3 | 2024 | 114 | 0.990 |
Why?
| | Cardiopulmonary Bypass | 8 | 2025 | 217 | 0.970 |
Why?
| | Tryptophan | 3 | 2024 | 183 | 0.950 |
Why?
| | Heart Septal Defects | 1 | 2026 | 12 | 0.940 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2026 | 369 | 0.890 |
Why?
| | Infant | 23 | 2025 | 10093 | 0.840 |
Why?
| | Cardiac Surgical Procedures | 6 | 2024 | 608 | 0.840 |
Why?
| | Acetamides | 1 | 2024 | 42 | 0.820 |
Why?
| | Nitric Oxide | 3 | 2024 | 883 | 0.800 |
Why?
| | Matrix Metalloproteinase 8 | 1 | 2023 | 8 | 0.800 |
Why?
| | Citrulline | 1 | 2024 | 45 | 0.790 |
Why?
| | Pyrazines | 1 | 2024 | 94 | 0.780 |
Why?
| | Infant, Newborn | 17 | 2026 | 6449 | 0.780 |
Why?
| | Arginine | 1 | 2024 | 263 | 0.730 |
Why?
| | Blood Proteins | 2 | 2020 | 239 | 0.730 |
Why?
| | Aortic Coarctation | 2 | 2023 | 76 | 0.720 |
Why?
| | Heart Bypass, Right | 1 | 2022 | 17 | 0.710 |
Why?
| | Child | 31 | 2026 | 22638 | 0.700 |
Why?
| | Infant, Premature, Diseases | 2 | 2023 | 113 | 0.700 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2025 | 427 | 0.670 |
Why?
| | Ventricular Function, Left | 4 | 2023 | 541 | 0.640 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2020 | 66 | 0.630 |
Why?
| | Magnetic Resonance Imaging | 9 | 2026 | 3917 | 0.630 |
Why?
| | Heart Diseases | 1 | 2023 | 341 | 0.620 |
Why?
| | Heart Function Tests | 1 | 2019 | 59 | 0.600 |
Why?
| | Humans | 63 | 2026 | 145625 | 0.580 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 22 | 0.570 |
Why?
| | Scurvy | 1 | 2019 | 17 | 0.570 |
Why?
| | Biomarkers | 9 | 2026 | 4329 | 0.570 |
Why?
| | Prospective Studies | 11 | 2024 | 8087 | 0.560 |
Why?
| | Atrial Function, Right | 3 | 2025 | 13 | 0.550 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2019 | 124 | 0.540 |
Why?
| | Ventricular Function, Right | 4 | 2026 | 300 | 0.530 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 340 | 0.520 |
Why?
| | Pediatrics | 2 | 2024 | 1122 | 0.490 |
Why?
| | Ventricular Remodeling | 1 | 2019 | 283 | 0.480 |
Why?
| | Retrospective Studies | 17 | 2025 | 17291 | 0.470 |
Why?
| | Male | 33 | 2026 | 73014 | 0.450 |
Why?
| | Magnetic Resonance Imaging, Cine | 4 | 2025 | 214 | 0.430 |
Why?
| | Echocardiography, Doppler | 2 | 2025 | 117 | 0.420 |
Why?
| | Female | 33 | 2026 | 79080 | 0.410 |
Why?
| | Treatment Outcome | 11 | 2025 | 11744 | 0.410 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2022 | 194 | 0.390 |
Why?
| | Pain | 1 | 2019 | 787 | 0.380 |
Why?
| | Computed Tomography Angiography | 2 | 2025 | 151 | 0.380 |
Why?
| | Adolescent | 17 | 2025 | 22451 | 0.370 |
Why?
| | Predictive Value of Tests | 8 | 2026 | 2097 | 0.370 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.360 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2025 | 119 | 0.350 |
Why?
| | Child, Preschool | 12 | 2026 | 11888 | 0.340 |
Why?
| | Acute Kidney Injury | 3 | 2026 | 861 | 0.330 |
Why?
| | Vasodilator Agents | 2 | 2025 | 326 | 0.320 |
Why?
| | Hypoxia | 3 | 2024 | 1209 | 0.310 |
Why?
| | Heart Failure | 1 | 2024 | 2323 | 0.310 |
Why?
| | Myocardial Contraction | 3 | 2020 | 292 | 0.310 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 519 | 0.310 |
Why?
| | Infant, Premature | 3 | 2025 | 622 | 0.300 |
Why?
| | Case-Control Studies | 5 | 2025 | 3633 | 0.300 |
Why?
| | Microfilament Proteins | 4 | 2003 | 135 | 0.290 |
Why?
| | Pulmonary Valve | 1 | 2010 | 100 | 0.290 |
Why?
| | Length of Stay | 4 | 2025 | 1342 | 0.280 |
Why?
| | Stents | 3 | 2025 | 551 | 0.270 |
Why?
| | Postoperative Complications | 5 | 2021 | 2962 | 0.260 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 2 | 2025 | 28 | 0.260 |
Why?
| | Arterial Pressure | 2 | 2025 | 130 | 0.250 |
Why?
| | Prognosis | 4 | 2026 | 4331 | 0.250 |
Why?
| | Tissue Engineering | 1 | 2010 | 439 | 0.240 |
Why?
| | Morbidity | 2 | 2024 | 317 | 0.230 |
Why?
| | Carrier Proteins | 4 | 2003 | 728 | 0.230 |
Why?
| | Stroke Volume | 3 | 2025 | 651 | 0.230 |
Why?
| | Vascular Stiffness | 2 | 2021 | 488 | 0.230 |
Why?
| | Palliative Care | 3 | 2025 | 1032 | 0.230 |
Why?
| | Proteomics | 2 | 2023 | 1202 | 0.220 |
Why?
| | SOXF Transcription Factors | 1 | 2024 | 16 | 0.210 |
Why?
| | Serotonin | 2 | 2024 | 297 | 0.210 |
Why?
| | Kynurenic Acid | 1 | 2024 | 18 | 0.210 |
Why?
| | Angioplasty, Balloon | 1 | 2025 | 92 | 0.210 |
Why?
| | Chorioamnionitis | 1 | 2025 | 50 | 0.210 |
Why?
| | Multidetector Computed Tomography | 1 | 2025 | 40 | 0.210 |
Why?
| | Graft Occlusion, Vascular | 1 | 2025 | 39 | 0.210 |
Why?
| | Norwood Procedures | 1 | 2025 | 33 | 0.210 |
Why?
| | Hemorrhage | 2 | 2021 | 824 | 0.210 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2025 | 145 | 0.200 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 26 | 0.200 |
Why?
| | History, 21st Century | 1 | 2024 | 224 | 0.190 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 39 | 0.190 |
Why?
| | Models, Cardiovascular | 2 | 2024 | 194 | 0.190 |
Why?
| | Vascular Resistance | 1 | 2024 | 365 | 0.190 |
Why?
| | History, 20th Century | 1 | 2024 | 330 | 0.190 |
Why?
| | Infant, Extremely Premature | 1 | 2023 | 67 | 0.190 |
Why?
| | Triglycerides | 1 | 2025 | 527 | 0.190 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2026 | 334 | 0.190 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2022 | 38 | 0.180 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 156 | 0.180 |
Why?
| | Atrioventricular Block | 1 | 2022 | 44 | 0.180 |
Why?
| | Phenylpropionates | 1 | 2022 | 27 | 0.170 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.170 |
Why?
| | Pyridazines | 1 | 2022 | 56 | 0.170 |
Why?
| | Transcriptome | 2 | 2026 | 1066 | 0.170 |
Why?
| | Phosphoproteins | 1 | 2003 | 319 | 0.170 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 16 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 473 | 0.170 |
Why?
| | Protein Conformation | 2 | 2003 | 914 | 0.170 |
Why?
| | Fetal Diseases | 1 | 2023 | 192 | 0.170 |
Why?
| | Amino Acids | 1 | 2025 | 513 | 0.170 |
Why?
| | Swine | 4 | 2026 | 821 | 0.170 |
Why?
| | Risk Factors | 5 | 2025 | 10840 | 0.170 |
Why?
| | Ventricular Function | 1 | 2021 | 53 | 0.170 |
Why?
| | Administration, Inhalation | 2 | 2021 | 567 | 0.170 |
Why?
| | Lung | 4 | 2025 | 4119 | 0.160 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2003 | 627 | 0.160 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 284 | 0.160 |
Why?
| | Postoperative Period | 1 | 2022 | 344 | 0.160 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 95 | 0.160 |
Why?
| | Pulmonary Atresia | 1 | 2020 | 23 | 0.160 |
Why?
| | Preoperative Period | 1 | 2020 | 150 | 0.150 |
Why?
| | Heart Atria | 1 | 2021 | 139 | 0.150 |
Why?
| | Proteome | 1 | 2024 | 520 | 0.150 |
Why?
| | Electrophysiological Phenomena | 1 | 2019 | 58 | 0.150 |
Why?
| | Metabolomics | 3 | 2021 | 737 | 0.150 |
Why?
| | Societies, Medical | 1 | 2024 | 901 | 0.150 |
Why?
| | Aortic Valve Stenosis | 1 | 2022 | 254 | 0.150 |
Why?
| | Mechanical Phenomena | 1 | 2019 | 80 | 0.140 |
Why?
| | Gingiva | 1 | 2019 | 25 | 0.140 |
Why?
| | Extracellular Matrix | 1 | 2023 | 564 | 0.140 |
Why?
| | Regional Blood Flow | 1 | 2021 | 507 | 0.140 |
Why?
| | Coronary Care Units | 1 | 2018 | 27 | 0.140 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 385 | 0.140 |
Why?
| | Cholecalciferol | 1 | 2019 | 60 | 0.140 |
Why?
| | Alkaline Phosphatase | 1 | 2019 | 144 | 0.140 |
Why?
| | Chest Pain | 1 | 2019 | 100 | 0.140 |
Why?
| | Endotoxemia | 1 | 2019 | 85 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 295 | 0.130 |
Why?
| | Endotoxins | 1 | 2019 | 215 | 0.130 |
Why?
| | Biomedical Research | 1 | 2024 | 724 | 0.130 |
Why?
| | Ascorbic Acid | 1 | 2019 | 183 | 0.130 |
Why?
| | Leg | 1 | 2019 | 243 | 0.120 |
Why?
| | Inflammation | 2 | 2025 | 2915 | 0.120 |
Why?
| | Heart Transplantation | 1 | 2023 | 679 | 0.120 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 588 | 0.120 |
Why?
| | Cohort Studies | 2 | 2024 | 6045 | 0.120 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2021 | 774 | 0.120 |
Why?
| | Risk | 1 | 2019 | 917 | 0.120 |
Why?
| | Iron | 1 | 2019 | 359 | 0.120 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 1997 | 104 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 574 | 0.110 |
Why?
| | Actins | 3 | 2003 | 422 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1318 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2019 | 586 | 0.100 |
Why?
| | Lung Diseases | 1 | 2021 | 787 | 0.100 |
Why?
| | Down Syndrome | 1 | 2021 | 529 | 0.100 |
Why?
| | Intubation, Intratracheal | 1 | 1997 | 328 | 0.100 |
Why?
| | Time Factors | 3 | 2021 | 7079 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 926 | 0.100 |
Why?
| | Blood Pressure | 1 | 2019 | 1761 | 0.090 |
Why?
| | Amino Acid Sequence | 4 | 2003 | 2088 | 0.090 |
Why?
| | Molecular Sequence Data | 4 | 2003 | 2835 | 0.080 |
Why?
| | Diastole | 2 | 2022 | 147 | 0.080 |
Why?
| | Purines | 2 | 2022 | 188 | 0.080 |
Why?
| | Drainage | 1 | 2011 | 187 | 0.080 |
Why?
| | Wounds and Injuries | 1 | 2019 | 956 | 0.080 |
Why?
| | Cell Count | 1 | 2010 | 315 | 0.080 |
Why?
| | Bile Duct Neoplasms | 1 | 2011 | 132 | 0.080 |
Why?
| | Adult | 4 | 2023 | 40821 | 0.070 |
Why?
| | Anastomosis, Surgical | 2 | 2021 | 161 | 0.070 |
Why?
| | Cholestasis | 1 | 2011 | 215 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2026 | 1790 | 0.070 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 2 | 2002 | 348 | 0.070 |
Why?
| | Animals | 8 | 2026 | 38030 | 0.070 |
Why?
| | Peptide Fragments | 2 | 2003 | 693 | 0.070 |
Why?
| | Metabolome | 2 | 2021 | 390 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3396 | 0.060 |
Why?
| | Kidney | 2 | 2026 | 1491 | 0.060 |
Why?
| | Sus scrofa | 1 | 2026 | 64 | 0.060 |
Why?
| | Keratan Sulfate | 1 | 2006 | 1 | 0.060 |
Why?
| | Histidine | 2 | 2003 | 66 | 0.060 |
Why?
| | Synovial Fluid | 1 | 2006 | 69 | 0.060 |
Why?
| | Protein Folding | 3 | 2002 | 281 | 0.060 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 143 | 0.060 |
Why?
| | RAW 264.7 Cells | 1 | 2025 | 51 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2026 | 4565 | 0.050 |
Why?
| | Circular Dichroism | 2 | 2002 | 149 | 0.050 |
Why?
| | Age Factors | 2 | 2025 | 3321 | 0.050 |
Why?
| | Drug Synergism | 1 | 2025 | 353 | 0.050 |
Why?
| | Organ Specificity | 1 | 2025 | 306 | 0.050 |
Why?
| | Hyaluronic Acid | 1 | 2006 | 226 | 0.050 |
Why?
| | Language Development | 1 | 2024 | 60 | 0.050 |
Why?
| | Vena Cava, Inferior | 1 | 2024 | 79 | 0.050 |
Why?
| | Syndrome | 1 | 2024 | 377 | 0.050 |
Why?
| | Erythrocyte Membrane | 1 | 2003 | 55 | 0.050 |
Why?
| | Models, Molecular | 3 | 2003 | 1571 | 0.050 |
Why?
| | Osteoarthritis | 1 | 2006 | 204 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2497 | 0.050 |
Why?
| | Vascular Remodeling | 1 | 2025 | 208 | 0.050 |
Why?
| | Serine | 1 | 2003 | 142 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2020 | 3930 | 0.050 |
Why?
| | Binding Sites | 2 | 2003 | 1306 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2002 | 834 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2025 | 887 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 483 | 0.050 |
Why?
| | Heart Arrest | 1 | 2026 | 410 | 0.040 |
Why?
| | Tadalafil | 1 | 2022 | 6 | 0.040 |
Why?
| | Pulmonary Circulation | 1 | 2024 | 431 | 0.040 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 81 | 0.040 |
Why?
| | Phenylalanine | 1 | 2002 | 69 | 0.040 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2022 | 41 | 0.040 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2021 | 17 | 0.040 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2002 | 193 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2002 | 369 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2002 | 295 | 0.040 |
Why?
| | Methionine | 1 | 2021 | 160 | 0.040 |
Why?
| | Niacinamide | 1 | 2021 | 103 | 0.040 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2020 | 34 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 46 | 0.040 |
Why?
| | Systole | 1 | 2020 | 179 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 1014 | 0.040 |
Why?
| | Gestational Age | 1 | 2023 | 989 | 0.040 |
Why?
| | Survival Rate | 2 | 2011 | 2078 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2025 | 2533 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2020 | 134 | 0.040 |
Why?
| | Aortic Valve | 1 | 2022 | 360 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 192 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1717 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2002 | 662 | 0.040 |
Why?
| | Time | 1 | 2019 | 85 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 1034 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2020 | 452 | 0.030 |
Why?
| | Electrocardiography | 1 | 2022 | 666 | 0.030 |
Why?
| | Myocardium | 1 | 2023 | 948 | 0.030 |
Why?
| | Escherichia coli | 1 | 2002 | 831 | 0.030 |
Why?
| | Electrophysiologic Techniques, Cardiac | 1 | 2018 | 82 | 0.030 |
Why?
| | Nevada | 1 | 1997 | 9 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1878 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2025 | 2910 | 0.030 |
Why?
| | Aorta | 1 | 2020 | 440 | 0.030 |
Why?
| | Poisson Distribution | 1 | 1997 | 77 | 0.030 |
Why?
| | Cytokines | 1 | 2025 | 2079 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2020 | 728 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2026 | 2591 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2018 | 419 | 0.030 |
Why?
| | Macrophages | 1 | 2025 | 1530 | 0.030 |
Why?
| | Thrombophlebitis | 1 | 1997 | 12 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1184 | 0.030 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 1997 | 39 | 0.030 |
Why?
| | United States | 2 | 2025 | 16041 | 0.030 |
Why?
| | Rats | 1 | 2025 | 5574 | 0.030 |
Why?
| | Confidence Intervals | 1 | 1997 | 328 | 0.030 |
Why?
| | Arthroplasty | 1 | 1997 | 60 | 0.030 |
Why?
| | Liver | 1 | 2025 | 1859 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1581 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2018 | 578 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1997 | 293 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 6021 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 1037 | 0.020 |
Why?
| | Oxygen | 1 | 2018 | 996 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2766 | 0.020 |
Why?
| | Pregnancy | 1 | 2025 | 7217 | 0.020 |
Why?
| | Retreatment | 1 | 2011 | 79 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5397 | 0.020 |
Why?
| | Chickens | 2 | 2002 | 169 | 0.020 |
Why?
| | Catheterization | 1 | 2011 | 178 | 0.020 |
Why?
| | Incidence | 1 | 1997 | 2910 | 0.020 |
Why?
| | Radiography, Interventional | 1 | 2011 | 127 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3678 | 0.020 |
Why?
| | Mice | 1 | 2025 | 18266 | 0.020 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2006 | 12 | 0.010 |
Why?
| | Protein Binding | 2 | 2002 | 2239 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 787 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 2011 | 8351 | 0.010 |
Why?
| | Autoantigens | 1 | 2006 | 426 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 14240 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 2002 | 131 | 0.010 |
Why?
| | Knee Joint | 1 | 2006 | 439 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 326 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 382 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 372 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2002 | 180 | 0.010 |
Why?
| | Titrimetry | 1 | 1999 | 12 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1999 | 72 | 0.010 |
Why?
| | Static Electricity | 1 | 1999 | 113 | 0.010 |
Why?
| | Solvents | 1 | 1999 | 112 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 1999 | 217 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2002 | 376 | 0.010 |
Why?
| | Temperature | 1 | 2002 | 633 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1999 | 357 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1553 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1361 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1999 | 533 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2018 | 0.010 |
Why?
| | Thermodynamics | 1 | 1999 | 418 | 0.010 |
Why?
| | Software | 1 | 2002 | 673 | 0.010 |
Why?
| | Case Management | 1 | 1997 | 66 | 0.010 |
Why?
| | Aged | 2 | 2011 | 26251 | 0.010 |
Why?
| | Middle Aged | 2 | 2011 | 36359 | 0.010 |
Why?
| | Population Surveillance | 1 | 1997 | 477 | 0.010 |
Why?
|
|
Frank's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|